NowRx aims to disrupt the pharmacy market
In a bid to disrupt traditional processes, NowRx will enable patients to re-order repeat prescriptions through utilising Amazon Alexa and Google Cloud technologies, according to recent reports.
The move will see traditional queues become eradicated within brick-and-mortar pharmacies, and will see prescriptions delivered to a user’s door. Obtaining approximately $2 million in seed funding back in June, NowRx is set to fully launch its service this month.
NowRx CEO Cary Breese has said: "Free same-day delivery provides a dramatically better customer experience, and is uniquely available from an on-demand pharmacy. Large chain pharmacies are reluctant to offer free delivery because of the essential incentive to attract customers into their brick and mortar locations so they can upsell them on all of the other products in the store."
- Pfizer and Cipla work to counteract the growing number of cancer cases in Africa
- China is looking at ways to eradicate bottlenecks in drug development
- Rising number of measles cases in the US raises important questions
"By operating inside highly automated, low-overhead warehouse locations, NowRx will be able to achieve the same or better operating margins as the largest players in the industry and, in fact, we are projecting profitability later this year.”
Furthermore, to appeal to a wider market, NowRx has an inbuilt functionality which deliver reminders for the required medication and refills.
In utilising the technology, users are able to order a repeat prescription through Alexa or Google Home. This request is accepted like a traditional card payment order once the patient’s prescription number is confirmed, and the required medication is delivered promptly. By encrypting any patient data, NowRx are also able to gain HIPAA compliancy by storing this vital patient data away from tech giants.
To further its customer base, the company aim to work with insurance providers with the support of pharmacists and doctors across the US and expand its warehouse operations as it gains increased revenue.
Introducing Dosis - the AI powered dosing platform
Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works.
When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing.
The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced.
What is the Strategic Anemia Advisor?
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease.
SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool.
What else is Dosis working on?
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs.
What are Dosis' strategic goals for the next 2-3 years?
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.
What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.